Health Policies

All Items

• New drug pricing criteria in Italy: considerations and proposals to support value and innovation

  Francesca Patarnello, Federico Villa

  131-133

  DOI: https://doi.org/10.33393/grhta.2021.2207

• Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

  Claudio Jommi, Antonio Addis, Nello Martini, Elena Nicod, Marcello Pani, Annalisa Scopinaro, Sabine Vogler

  114-119

  DOI: https://doi.org/10.33393/grhta.2021.2278

• The future of Funds for Innovative Medicines: results from a Delphi Study

  Claudio Jommi, Patrizio Armeni, Arianna Bertolani, Francesco Costa, Monica Otto

  22-28

  DOI: https://doi.org/10.33393/grhta.2021.2219

• The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020

  Paola Raimondo, Giorgio Casilli, Martina Isernia, Dario Lidonnici, Roberto Ravasio, Virginia Ronco, Elena Lanati

  109-114

  DOI: https://doi.org/10.33393/grhta.2020.2173

• Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costs

  Americo Cicchetti, Domenico Addesso, Filippo Elvino Leone, Antonino Amato, Luca Angerame, Angelo D'Aversa, Mario Fraticelli, Carlo Nicora, Eleonora Sfreddo, Mariangela Fumarola, Roberta Porcino, Gabriella Cocciolo, Simona Re, Sergio Scaccabarozzi

  26-32

  DOI: https://doi.org/10.33393/grhta.2020.709

• Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valore AIFA’s new approach to multidimensional value determination

  Oriana Ciani, Carlo Federici, Giulia Fornaro, Carla Rognoni

  9-13

  DOI: https://doi.org/10.33393/grhta.2020.2102